Decision: AcceptLiving evidence briefMay 29, 2026
This synthesis tests the thesis that evidence for Circadian light timing is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Circadian light timing—the scheduling of bright-light exposure relative to the endogenous sleep–wake cycle—has emerged as a modifiable determinant of metabolic, inflammatory, and longevity-related outcomes, yet its net effect in aging populations remains contested. To address this question, we conducted an AI-assisted structured evidence synthesis with a reproducible audit trail, systematically integrating observational, preclinical, and mechanistic data from 25 curated reference papers on circadian light timing and aging-relevant endpoints. Translational relevance to humans remains uncertain. The synthesis of cross-study disagreements across outcome classes reveals that negative longevity signals from observational cohorts coexist with null cardiometabolic and contextual findings, creating an evidentiary pattern where mechanistic plausibility—supported by preclinical and biomarker data—has not yet been translated into consistent human hard-endpoint outcomes. We conclude that circadian light timing likely exerts a biologically real influence on aging trajectories through immune, amyloid, and telomere-related pathways, but the human evidence is constrained by obse
Proof: provenance chain + sha256:84f93cfd9ca6...
Decision: AcceptLiving evidence briefMay 29, 2026
This synthesis tests the thesis that evidence for Cold exposure brown fat is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes cold exposure brown fat as an aging-related intervention across 37 included source papers and 1333 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 23 adjacent clinical sources, and 9 mechanistic or model-system sources, with 167 cross-study disagreements across the evidence base. Positive study-level signals concentrate in immune, null signals in contextual adjacent evidence, cardiometabolic, immune, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that cold exposure brown fat remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. The study-level stru
Proof: provenance chain + sha256:5714d0d9ca9c...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Coenzyme Q10 ubiquinol is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes coenzyme q10 ubiquinol as an aging-related intervention across 63 included source papers and 3843 high-confidence extracted claims. The evidence profile contains 7 direct clinical sources, 24 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 283 cross-study disagreements across the evidence base. Positive study-level signals concentrate in longevity, contextual adjacent evidence, mortality and survival, null signals in dosing and pharmacokinetics, contextual adjacent evidence, safety and comorbidity, and negative signals in cardiometabolic. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that coenzyme q10 ubiquinol remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not
Proof: provenance chain + sha256:e8cdfb635f11...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for CGM glucose variability is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Glucose variability, increasingly captured by continuous glucose monitoring (CGM), is hypothesized as an independent driver of cardiometabolic risk in diabetes, yet whether this association translates to a clinically actionable target in aging populations remains contested. This synthesis applied a structured, AI-assisted evidence mapping approach to curate 51 reference papers, using a transparent audit trail to identify effect directions and extract quantitative endpoints across cardiometabolic, safety, and contextual outcome domains. The evidence base reveals a fundamental tension: mechanistic plausibility linking glucose variability to oxidative stress and endothelial dysfunction is strong, but the largest real-world datasets and meta-analyses produce mixed or modest effect sizes, with many comparisons reaching null findings across both cardiometabolic and contextual outcome classes. Critically, the source corpus contains no direct RCT evidence linking CGM-derived variability reduction to hard aging endpoints such as mortality or functional decline in older adults; the closest approximations derive from secondary analyses of diabetes management trials or ICU
Proof: provenance chain + sha256:3346602af5f9...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Akkermansia muciniphila is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes akkermansia muciniphila as an aging-related intervention across 78 included source papers and 2155 high-confidence extracted claims. The evidence profile contains 1 direct clinical source, 47 adjacent clinical sources, and 19 mechanistic or model-system sources, with 1184 cross-study disagreements across the evidence base. Positive study-level signals concentrate in contextual adjacent evidence, immune and inflammation, null signals in contextual adjacent evidence, immune and inflammation, cardiometabolic, and negative signals in immune, contextual adjacent evidence. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that akkermansia muciniphila remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Proof: provenance chain + sha256:d67aeee6b6cf...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for ARBs longevity is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes arbs longevity as an aging-related intervention across 71 included source papers and 4116 high-confidence extracted claims. The evidence profile contains 1 direct clinical source, 48 adjacent clinical sources, and 1 mechanistic or model-system source, with 665 cross-study disagreements across the evidence base. Positive study-level signals concentrate in contextual adjacent evidence, safety and comorbidity, cardiometabolic, null signals in contextual adjacent evidence, safety and comorbidity, cardiometabolic, and negative signals in cardiometabolic, mortality and survival. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that arbs longevity remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in
Proof: provenance chain + sha256:3fd5cb574764...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Blue zones diet lifestyle is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes blue zones diet lifestyle as an aging-related intervention across 50 included source papers and 1736 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 40 adjacent clinical sources, and 4 mechanistic or model-system sources, with 528 cross-study disagreements across the evidence base. Positive study-level signals concentrate in deficiency prevalence, longevity, null signals in contextual adjacent evidence, longevity, mortality and survival, and negative signals in contextual adjacent evidence. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that blue zones diet lifestyle remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Proof: provenance chain + sha256:839f9db77a98...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Bempedoic acid is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Whether bempedoic acid—an ATP-citrate lyase inhibitor that lowers LDL cholesterol upstream of HMG-CoA reductase—confers longevity benefits beyond vascular risk reduction remains an open question with direct implications for aging pharmacology. This synthesis employed an AI-assisted structured evidence appraisal with full audit trail, screening 49 curated reference papers and mapping effect directions, p-values, and tensions across cardiometabolic, immune, longevity, and safety outcome classes. Renal safety data show that three months of bempedoic acid treatment does not affect cystatin C–based glomerular filtration rate estimates, and long-term Japanese cohort data over 52 weeks report an acceptable tolerability profile without signal for treatment-emergent adverse events (Serio 2025; Masuda 2025). We conclude that mechanistic plausibility for a longevity benefit of bempedoic acid is supported by its upstream lipid-pathway inhibition and demonstrated MACE reduction, but the absence of dedicated hard-mortality trials, combined with divergent immune-endpoint evidence, means the anti-aging case remains incomplete and cannot yet displace the null hypothesis. Definitive resol
Proof: provenance chain + sha256:fe5ba1ba236d...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Allostatic load is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Allostatic load (AL) reflects cumulative biological burden from chronic stress exposure, yet its anti-aging promise remains unsettled across human and preclinical domains. To adjudicate this tension, we conducted an AI-assisted structured evidence synthesis with full audit trail, integrating 50 curated references across mechanistic and clinical outcomes. In human trials, creatine plus β-hydroxy-β-methylbutyrate preserved glutathione redox balance in older adults (P < 0.05), aligning with mechanistic expectations, though effect direction remains unclear. Cardiometabolic outcomes similarly show null findings, including in polycystic ovary syndrome trials where combined training did not improve metabolic biomarkers. Across cross-study disagreements identified, mechanistic plausibility coexists with mixed or sparse human-RCT evidence, underscoring the boundary conditions of AL interventions. Across the corpus, the evidence supports a model where mechanistic plausibility is strongest in preclinical contexts, while human applicability remains contingent on outcome class and intervention specificity. Critical gaps include the lack of harmonized AL indices in clinical trials an
Proof: provenance chain + sha256:a0f1877a50a0...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for ACE inhibitors aging is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Angiotensin-converting enzyme (ACE) inhibitors are widely prescribed for hypertension, yet whether they confer direct anti-aging benefits—attenuating frailty, preserving muscle function, or extending lifespan beyond blood-pressure control—remains debated. This synthesis applied a structured, AI-assisted evidence-synthesis approach with an auditable trail to integrate 47 curated reference papers spanning randomized trials, observational cohorts, and preclinical mechanistic studies on ACE inhibitors and aging-related outcomes. Functional aging endpoints were similarly ambiguous: ACE inhibitor therapy did not improve gait-speed reserve beyond statin effects in older adults (Spiegeleer 2025), and in the LACE trial ACE I/D genotype associated with grip and quadriceps strength in sarcopenic men but ACE inhibitor treatment itself did not produce a significant strength response (Rossios 2023). Importantly, no direct human trial with aging-specific primary endpoints—such as frailty incidence, sarcopenia progression, or all-cause longevity in non-diseased older adults—was identified in this synthesis. The mechanistic plausibility that ACE inhibition modulates inflammation, e
Proof: provenance chain + sha256:59fe55f4d5ed...
Decision: AcceptLiving evidence briefMay 27, 2026
This synthesis tests the thesis that evidence for Aspirin geroprotection is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Aspirin is widely consumed for cardiovascular prophylaxis, yet its potential as a geroprotective agent—attenuating age-related inflammation, frailty, and multimorbidity—remains unresolved despite decades of mechanistic speculation. This synthesis integrated 57 curated reference papers spanning systematic reviews, meta-analyses, randomized trials, and observational cohorts, using an AI-assisted structured evidence synthesis approach with audit trail to map aspirin's effects across cardiometabolic, immune, frailty, and pharmacokinetic outcome domains. The cross-study disagreement map across 57 papers identified 274 cross-study disagreements between outcome classes, with the sharpest disagreements in dosing–pharmacokinetics (severity 4) and contextual outcomes (severity 4–5), reflecting fundamental heterogeneity in aspirin's dose–response and indication-specific effects. While aspirin demonstrates mechanistic plausibility for geroprotection through COX-mediated inflammation resolution and skeletal muscle inflammation hastening following acute injury, the current human evidence—including large randomized trials and cohort studies spanning thousands of participants—do
Proof: provenance chain + sha256:088139d96ab5...
Decision: AcceptLiving evidence briefMay 26, 2026
Rapamycin, an mTOR pathway inhibitor, has emerged as a leading candidate geroprotective agent, yet translating its robust preclinical lifespan benefits to humans requires reconciling mechanistic promise with functional and safety trade-offs. We conducted a structured evidence synthesis across curated preclinical, clinical, and observational sources, applying transparent inclusion criteria and an audit trail to adjudicate tensions between mechanistic plausibility and clinical signal. Pharmacokinetic analyses of real-world low-dose cohorts reveal considerable inter-individual variability in trough blood rapamycin levels, with compounded formulations showing different bioavailability profiles than commercial generics (P < 0.001 for formulation comparisons; Harinath 2025), a finding that complicates dose standardization across aging-relevant trials. On the mechanistic side, additive geroprotection has been demonstrated when rapamycin is combined with trametinib (Gkioni 2025, multiple endpoints at P < 0.05), and even two weeks of treatment increased ovarian lifespan in young and middle-aged female mice (Dou 2017, P < 0.05), while rapamycin reversed age-related vascular dysfunction in old B6D2F1 mice (P < 0.05 across endpoints; Lesniewski 2016). The weight of evidence supports rapamycin's mechanistic plausibility as a geroprotector—autophagy induction, senescence suppression, and imm
Proof: provenance chain + sha256:1a409c7246c3...
Decision: AcceptLiving evidence briefMay 26, 2026
This synthesis tests the thesis that evidence for Caloric restriction is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Caloric restriction (CR) is the most robustly replicated lifespan-extending intervention in animal models, yet its translational value for human aging and cardiometabolic health remains a central debate in geroscience. This synthesis applies a structured, audit-traced evidence approach to systematically appraise the published literature, prioritizing mechanistic plausibility against functional outcomes from human trials and large observational cohorts. Synthesis of 171 curated studies reveals that CR consistently improves cardiometabolic markers, with mean arterial pressure (P < 0.05) and lipid-related risk factors (P < 0.05) significantly decreasing after 12 weeks of intervention (Abdollahpour 2025, Huffman 2022). Anthropometric benefits are robustly demonstrated, as CR in women with obesity (Pescari 2024) and postmenopausal cohorts (Seimon 2019) significantly reduced body weight and fat mass (P < 0.001), though a significant proportion of weight loss is attributed to lean mass reduction. The tension between mechanistic longevity benefits and clinical functional trade-offs is stark: CR induced positive cardiometabolic shifts (Yi 2025) yet failed to maintain bone mi
Proof: provenance chain + sha256:5b7983380e97...
Decision: AcceptLiving evidence briefMay 18, 2026
This synthesis tests the thesis that evidence for Aerobic exercise is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.
Aerobic exercise is widely promoted for healthy aging, yet the evidence linking it to cardiometabolic and functional outcomes in older adults remains heterogeneous, raising the question of whether mechanistic plausibility translates into consistent clinical benefit.
This synthesis applied a structured, AI-assisted evidence appraisal to 129 curated reference papers spanning observational cohorts, systematic reviews, and meta-analyses, with each claim anchored to sources and effect-direction coding.
Metformin co-administration further illustrates the tension: in older adults completing aerobic training, metformin blunted VO₂peak improvements (P = 0.08) while preserving insulin-sensitivity gains (P < 0.05), indicating that drug–exercise interaction can selectively suppress mitochondrial adaptation (Konopka 2019).
A systematic review of long-term aerobic exercise reported improved vascular function into old age with a pooled effect (P < 0.001), yet individual studies frequ
Proof: provenance chain + sha256:00618a66edfa...